Saliva Dipstick Predicts Heart Failure Risk
|
By HospiMedica International staff writers Posted on 04 Sep 2019 |

Image: The two parts of the ESN device (Photo courtesy of Adam R. Thomas/RMIT).
A handheld diagnostic stick with embedded nano-sensors detects biomarkers that can accurately predict the risk of heart disease from saliva.
The ESN Cleer (Melbourne, Australia) device, developed in collaboration with the Innovative Manufacturing Cooperative Research Centre (IMCRC; Melbourne, Australia) and RMIT University (RMIT; Melbourne, Australia), is based on sensing technology originally developed at the RMIT Micro Nano Research Facility. A combination of novel nanomaterials, micro-electrodes, and innovative surface treatments were used to create the sensors, which can be tailored to measure biomarkers of interest, from medically recognized inflammatory markers to proprietary panels that improve prediction accuracy.
To use the device, the user unsnaps the top, which acts as a consumable saliva specimen collector and holds the biosensor array. The end is licked and replaced into the reusable electronics stick, which controls the analysis. After biomarker identification, the result is sent to a dedicated app installed onto a smartphone or tablet device. The app offers multifaceted features, including disease risk level detection report, immediate doctors communications support, an age/demographic statistical comparison, health tracking capabilities, health and wellbeing related informatics, a community interactive interface, and user feedback capabilities.
“Of the 400 million people who suffer from cardiovascular disease globally, only sixteen% of cases are due to genetic traits. This underlines how much room there is to improve on screening and prevention, which is where this device could have such an impact,” said Leopoldt de Bruin, CEO of ESN Cleer. “We’re really pleased to be able to bring these strands together in addressing such a major global health challenge.”
“Often, blood tests are only conducted after a heart failure episode. Such reactive testing is too late, leaving people with debilitating illness or leading to deaths,” said co-director of the RMIT Functional Materials and Microsystems Research Group, Professor Sharath Sriram, PhD. “The ESN Cleer device is able to measure biomarker concentrations a thousand times more accurately than levels founds in human bodily fluids. Prevention is always better than cure, which is where this technology comes in, adding accurate prediction to the mix.”
Related Links:
ESN Cleer
Innovative Manufacturing Cooperative Research Centre
RMIT University
The ESN Cleer (Melbourne, Australia) device, developed in collaboration with the Innovative Manufacturing Cooperative Research Centre (IMCRC; Melbourne, Australia) and RMIT University (RMIT; Melbourne, Australia), is based on sensing technology originally developed at the RMIT Micro Nano Research Facility. A combination of novel nanomaterials, micro-electrodes, and innovative surface treatments were used to create the sensors, which can be tailored to measure biomarkers of interest, from medically recognized inflammatory markers to proprietary panels that improve prediction accuracy.
To use the device, the user unsnaps the top, which acts as a consumable saliva specimen collector and holds the biosensor array. The end is licked and replaced into the reusable electronics stick, which controls the analysis. After biomarker identification, the result is sent to a dedicated app installed onto a smartphone or tablet device. The app offers multifaceted features, including disease risk level detection report, immediate doctors communications support, an age/demographic statistical comparison, health tracking capabilities, health and wellbeing related informatics, a community interactive interface, and user feedback capabilities.
“Of the 400 million people who suffer from cardiovascular disease globally, only sixteen% of cases are due to genetic traits. This underlines how much room there is to improve on screening and prevention, which is where this device could have such an impact,” said Leopoldt de Bruin, CEO of ESN Cleer. “We’re really pleased to be able to bring these strands together in addressing such a major global health challenge.”
“Often, blood tests are only conducted after a heart failure episode. Such reactive testing is too late, leaving people with debilitating illness or leading to deaths,” said co-director of the RMIT Functional Materials and Microsystems Research Group, Professor Sharath Sriram, PhD. “The ESN Cleer device is able to measure biomarker concentrations a thousand times more accurately than levels founds in human bodily fluids. Prevention is always better than cure, which is where this technology comes in, adding accurate prediction to the mix.”
Related Links:
ESN Cleer
Innovative Manufacturing Cooperative Research Centre
RMIT University
Latest Critical Care News
- Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreSurgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







